Identification of Escherichia coli β-glucuronidase inhibitors from Polygonum cuspidatum Siebold & Zucc.
DOI:
https://doi.org/10.1590/s2175-97902022e21394Keywords:
β-glucuronidase, Polygonum cuspidatum Siebold & Zucc., Trans-resveratrol 4’-O-β-D-glucopyranoside, (-)-Epicatechin gallate, Inhibitory mechanismAbstract
Gut bacterial β-glucuronidase (GUS) can reactivate xenobiotics that exert enterohepatic circulation- triggered gastrointestinal tract toxicity. GUS inhibitors can alleviate drug-induced enteropathy and improve treatment outcomes. We evaluated the inhibitory effect of Polygonum cuspidatum Siebold & Zucc. and its major constituents against Escherichia coli GUS (EcGUS), and characterized the inhibitory mechanism of each of the components. Trans-resveratrol 4’-O-β-D-glucopyranoside (HZ-1) and (-)-epicatechin gallate (HZ-2) isolated from P. cuspidatum were identified as the key components and potent inhibitors. These two components displayed strong to moderate inhibitory effects on EcGUS, with Ki values of 9.95 and 1.95 μM, respectively. Results from molecular docking indicated that HZ-1 and HZ-2 could interact with the key residues Asp163, Ser360, Ile 363, Glu413, Glu504, and Lys 568 of EcGUS via hydrogen bonding. Our findings demonstrate the inhibitory effect of P. cuspidatum and its two components on EcGUS, which supported the further evaluation and development of P. cuspidatum and its two active components as novel candidates for alleviating drug-induced damage in the mammalian gut.
Downloads
References
Awolade P, Cele N, Kerru N, Gummidi L, Oluwakemi E, Singh P. Therapeutic significance of beta-glucuronidase activity and its inhibitors: A review. Eur J Med Chem. 2020;187:111921
Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148:104398.
Bhatt AP, Pellock SJ, Biernat KA, Walton WG, Wallace BD, Creekmore BC, et al. Targeted inhibition of gut bacterial beta-glucuronidase activity enhances anticancer drug efficacy. Proc Natl Acad Sci U S A. 2020;117(13):7374-7381.
Bralley EE, Greenspan P, Hargrove JL, Wicker L, Hartle DK. Topical anti-inflammatory activity of Polygonum cuspidatum extract in the TPA model of mouse ear inflammation. J Inflamm-Lond. 2008;5:1.
Chamseddine AN, Ducreux M, Armand JP, Paoletti X, Satar T, Paci A, et al. Intestinal bacterial beta-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. Pharmacol Ther. 2019;199:1-15.
Cheng KW, Tseng CH, Yang CN, Tzeng CC, Cheng TC, Leu YL, et al. Specific inhibition of bacterial beta-glucuronidase by pyrazolo[4,3-c]quinoline derivatives via a pH-dependent manner to suppress chemotherapy-induced intestinal toxicity. J Med Chem. 2017;60(22):9222-9238.
Clarke G, Sandhu KV, Griffin BT, Dinan TG, Cryan JF, Hyland NP. Gut reactions: Breaking down xenobiotic- microbiome interactions. Pharmacol Rev. 2019;71(2):198-224.
Ervin SM, Hanley RP, Lim L, Walton WG, Pearce KH, Bhatt AP, et al. Targeting regorafenib-induced toxicity through inhibition of gut microbial beta-glucuronidases. ACS Chem Biol. 2019;14(12):2737-2744.
Feng L, Yang YL, Huo XK, Tian XG, Feng YJ, Yuan HW, et al. Highly selective NIR probe for intestinal beta- glucuronidase and high-throughput screening inhibitors to therapy intestinal damage. Acs Sensors. 2018;3(9):1727-1734.
Hahn RZ, Antunes MV, Verza SG, Perassolo MS, Suyenaga ES, Schwartsmann G, et al. Pharmacokinetic and pharmacogenetic markers of irinotecan toxicity. Curr Med Chem. 2019;26(12):2085-2107.
He X, Zhao WY, Shao B, Zhang BJ, Liu TT, Sun CP, et al. Natural soluble epoxide hydrolase inhibitors from Inula helenium and their interactions with soluble epoxide hydrolase. Int J Biol Macromol. 2020;158:1362-1368.
Hicks LD, Hyatt JL, Stoddard S, Tsurkan L, Edwards CC, Wadkins RM, et al. Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-Ethyl- 10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) ToxicityJ Med Chem . 2009;52(12):3742- 3752.
Hou XD, Song LL, Cao YF, Wang YN, Zhou Q, Fang SQ, et al. Pancreatic lipase inhibitory constituents from Fructus Psoraleae. Chin J Nat Med. 2020;18(5):369-378.
Hu WH, Chan GKL, Lou JS, Wu QY, Wang HY, Duan R, et al. The extract of Polygoni Cuspidati Rhizoma et Radix suppresses the vascular endothelial growth factor-induced angiogenesis. Phytomedicine. 2018;42:135-143.
Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101(4):847-854.
Jariwala PB, Pellock SJ, Goldfarb D, Cloer EW, Artola M, Simpson JB, et al. Discovering the microbial enzymes driving drug toxicity with activity-based protein profiling. ACS Chem Biol . 2020;15(1):217-225.
Li XW. Chemical ecology-driven discovery of bioactive marine natural products as potential drug leads. Chin J Nat Med . 2020;18(11):837-838.
Liu LT, Zheng G-J, Zhang WG, Guo G, Wu M. Clinical study on treatment of carotid atherosclerosis with extraction of polygoni cuspidati rhizoma et radix and crataegi fructus: a randomized controlled trial. Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China J Chin Mater Med. 2014;39(6):1115-1119.
Liu S, Zhang X-x, Zhuang S, Li C-h, Li Y-b. Effect of polygoni cuspidati rhizoma et radix and its ingredient resveratrol on experimental autoimmune myasthenia gravis by suppressing immune response. Chin Herbal Med. 2016;8(3):251-258.
Lu Y, Suh SJ, Li X, Hwang SL, Li Y, Hwangbo K, et al. Citreorosein, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, attenuates cyclooxygenase-2-dependent prostaglandin D-2 generation by blocking Akt and JNK pathways in mouse bone marrow- derived mast cells. Food Chem Toxicol. 2012;50(3-4):913-919.
Pellock SJ, Redinbo MR. Glucuronides in the gut: Sugar- driven symbioses between microbe and host. J Biol Chem. 2017;292(21):8569-8576.
Peng W, Qin RX, Li XL, Zhou H. Botany, phytochemistry, pharmacology, and potential application of Polygonum cuspidatum Sieb.et Zucc. A review. J Ethnopharmacol. 2013;148(3):729-745.
Pollet RM, D’Agostino EH, Walton WG, Xu YM, Little MS, Biernat KA, et al. An atlas of beta-glucuronidases in the human intestinal microbiome. Structure. 2017;25(7): 967-977.
Shi JW, Li ZZ, Wu JS, Jin WY, Chang XY, Sun H, et al. Identification of the bioactive components of Banxia Xiexin Decoction that protect against CPT-11-induced intestinal toxicity via UPLC-based spectrum-effect relationship analyses. J Ethnopharmacol. 2021;266:113421.
Singh A, Raju R, Mrad M, Reddell P, Munch G. The reciprocal EC50 value as a convenient measure of the potency of a compound in bioactivity-guided purification of natural products. Fitoterapia. 2020;143:104598.
Song PF, Zhu YD, Ma HY, Wang YN, Wang DD, Zou LW, et al. Discovery of natural pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1. Fitoterapia. 2019;137:104199.
Sun CP, Yan JK, Yi J, Zhang XY, Yu ZL, Huo XK, et al. The study of inhibitory effect of natural flavonoids toward beta-glucuronidase and interaction of flavonoids with beta- glucuronidase. Int J Biol Macromol . 2020;143:349-358.
Sun CP, Zhang J, Zhao WY, Yi J, Yan JK, Wang YL, et al. Protostane-type triterpenoids as natural soluble epoxide hydrolase inhibitors: Inhibition potentials and molecular dynamics. Bioorg Chem. 2020;96:103637.
Tao WQ, Zhou ZG, Zhao B, Wei TY. Simultaneous determination of eight catechins and four theaflavins in green, black and oolong tea using new HPLC-MS-MS method. J Pharm Biomed Anal. 2016;131:140-145.
Tian XG, Yan JK, Sun CP, Li JX, Ning J, Wang C, et al. Amentoflavone from Selaginella tamariscina as a potent inhibitor of gut bacterial β-glucuronidase: Inhibition kinetics and molecular dynamics stimulation. Chem Biol Interact. 2021;340:109453.
Tobin P, Clarke S, Seale JP, Lee S, Solomon M, Aulds S, et al. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. Br J Clin Pharmacol. 2006;62(1):122-129.
Wallace BD, Wang HW, Lane KT, Scott JE, Orans J, Koo JS, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330(6005):831-835.
Wang J, Feng WW, Tang F, Ao H, Peng C. Gut microbial transformation, a potential improving factor in the therapeutic activities of four groups of natural compounds isolated from herbal medicines. Fitoterapia . 2019;138:104293.
Weng ZM, Wang P, Ge GB, Dai ZR, Wu DC, Zou LW, et al. Structure -activity relationships of flavonoids as natural inhibitors against E. coli beta-glucuronidase. Food Chem Toxicol . 2017;109:975-983.
Yi J, Bai R, An Y, Liu TT, Liang JH, Tian XG, et al. A natural inhibitor from Alisma orientale against human carboxylesterase 2: Kinetics, circular dichroism spectroscopic analysis, and docking simulation. Int J Biol Macromol . 2019;133:184-189.
Zhao XH, Tao JH, Zhang T, Jiang SR, Wei W, Han HP, et al. Resveratroloside alleviates postprandial hyperglycemia in diabetic mice by competitively inhibiting alpha-glucosidase. J Agric Food Chem. 2019;67(10):2886-2893.
Zhang J, Lian JH, Zhao JC, Wang YL, Dong PP, Liu XG, et al. Xylarianins A-D from the endophytic fungus Xylaria sp SYPF 8246 as natural inhibitors of human carboxylesterase 2. Bioorg Chem . 2018;81:350-355.
Zhong JC, Li XB, Lyu WY, Ye WC, Zhang DM. Natural products as potent inhibitors of hypoxia-inducible factor-1 alpha in cancer therapy. Chin J Nat Med . 2020;18(9):696-703.
Zhou TS, Wei B, He M, Li YS, Wang YK, Wang SJ, et al. Thiazolidin-2-cyanamides derivatives as novel potent Escherichia coli beta-glucuronidase inhibitors and their structure-inhibitory activity relationships. J Enzyme Inhib Med Chem. 2020;35(1):1736-1742.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
How to Cite
Funding data
-
National Key Research and Development Program of China
Grant numbers 2018YFC1705900
